MedX Health Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA5850901037
CAD
0.06
-0.01 (-20.0%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 18 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.81

stock-summary
Return on Equity

52.91%

stock-summary
Price to Book

-1.81

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.69%
0%
-7.69%
6 Months
-29.41%
0%
-29.41%
1 Year
-7.69%
0%
-7.69%
2 Years
14.29%
0%
14.29%
3 Years
9.09%
0%
9.09%
4 Years
-57.14%
0%
-57.14%
5 Years
-60.0%
0%
-60.0%

MedX Health Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
1.05%
EBIT to Interest (avg)
-2.76
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.79
Sales to Capital Employed (avg)
-0.29
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-2.01
EV to EBIT
-8.43
EV to EBITDA
-8.56
EV to Capital Employed
-15.20
EV to Sales
24.86
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bullish
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs -50.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -44.44% vs 35.71% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.90",
          "val2": "-0.70",
          "chgp": "-28.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.20",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.30",
          "val2": "-0.90",
          "chgp": "-44.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-10,528.00%",
          "val2": "-7,059.40%",
          "chgp": "-346.86%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 19.57% vs 9.80% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "0.50",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.30",
          "val2": "-3.00",
          "chgp": "23.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.30",
          "val2": "2.20",
          "chgp": "-40.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.70",
          "val2": "-4.60",
          "chgp": "19.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,704.40%",
          "val2": "-6,632.50%",
          "chgp": "192.81%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary

Jun'25
Jun'24
Change(%)
Net Sales
0.10
0.10
Operating Profit (PBDIT) excl Other Income
-0.90
-0.70
-28.57%
Interest
0.40
0.20
100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.30
-0.90
-44.44%
Operating Profit Margin (Excl OI)
-10,528.00%
-7,059.40%
-346.86%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs -50.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -44.44% vs 35.71% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
0.50
0.50
Operating Profit (PBDIT) excl Other Income
-2.30
-3.00
23.33%
Interest
1.30
2.20
-40.91%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.70
-4.60
19.57%
Operating Profit Margin (Excl OI)
-4,704.40%
-6,632.50%
192.81%
USD in Million.
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 19.57% vs 9.80% in Dec 2023

stock-summaryCompany CV
About MedX Health Corp. stock-summary
stock-summary
MedX Health Corp.
Pharmaceuticals & Biotechnology
MedX Health Corp. is a medical device company. The Company is focused on research, development, manufacturing and distribution of phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode (LED). Its products are offered to the rehabilitation market for treating pain, tissue damage, swelling and inflammation. It offers SIAscopy, which is a medical device that is used to scan suspicious moles and lesions. Its SIMSYS-MoleMate Skin Imaging System is a non-invasive skin screening procedure for moles and lesions. Its SIMSYS uses SIAscopy providing detail and information from approximately two millimeters beneath the skin. Its MoleMate is a non-invasive, rapid and painless screening device that has been designed with and for general practitioners and skin specialists. Its SIAMETRICS allows cosmetic formulators and active ingredient manufacturers to measure and quantify the concentrations of melanin, hemoglobin and collagen in living human skin.
Company Coordinates stock-summary
Company Details
1495 Bonhill Road, Unit 1 , MISSISSAUGA ON : L5T1M2
stock-summary
Tel: 1 905 6704428
stock-summary
Registrar Details